Document is current

Article History

Received: 4 April 2022

Accepted: 3 October 2022

First Online: 8 October 2022

Declarations

:

: The study protocol was approved by the ethics committee in each participating hospital and complied with the Declaration of Helsinki and Good Clinical Practice guidelines. For the patients who received galcanezumab for prevention of cluster headache before the IRB approval, IRB allowed the process of written informed consent to be waived due to retrospective data collection and fully anonymity. After IRB approval, all patients were given full explanation of the study purposes and provided written informed consent before their voluntary participation.

: Not applicable.

: Dr. Mo was involved as a site investigator of multicenter trial sponsored Biohaven Asia Pacific Ltd. Dr. Kim was a principal investigator for a multicenter trial sponsored by Otsuka Korea, Novartis International AG, Ildong Pharm and Eli Lilly and Company. BKK worked as an advisory member for Lundbeck Korea, Sanofi Korea, Teva Korea and received lecture honoraria from GSK Korea, SK Chemicals, Allergan Korea and Yuyu Pharmaceutical Company in the past 24 months. Dr. Moon reported no conflict of interest.Dr. Cho was a site investigator of a multicenter trial sponsored by Allergan, Abbvie Inc., Ildong Pharmaceutical Co., LTD, Novartis International AG, Eli Lilly and Company, Hyundaipharm. Co. Ltd., Biohaven Asia Pacific Ltd., and H. Lundbeck A/S (Lundbeck), and received lecture honoraria from Allergan Korea, WhanIn Pharm Co., LTD, Boryung Pharmaceutical Co.,Ltd., Shinpoong Pharma. Co., Ltd., Yuyu Pharmaceutical Company, and SK chemicals in the past 24 months.